Argus
•
Oct 28, 2026
KRYS: Lowering target price to $353.00
Summary
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: BridgeBio Pharma, Inc.
Oct 30, 2026
•
BBIO
Analyst Report: BridgeBio Pharma, Inc.
Oct 28, 2026
•
BBIO
PTGX: Raising target price to $148.00
Oct 28, 2026
•
PTGX
PTGX: What does Argus have to say about PTGX?
Oct 21, 2026
•
PTGX
PTGX: Lowering target price to $145.00
Oct 14, 2026
•
PTGX
